Radioimmunotherapeutic approaches for leukemia: The past, present and future

Cytotherapy

Volumn 10, Issue 1, 2008, Pages 13-20

  Pagel, J M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD33; CD45; CD66; Leukemia; Radioimmunotherapy; Radiolabeled antibody

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; ASTATINE 211; BISMUTH 213; BUSULFAN; CD45 ANTIGEN; COPPER 64; COPPER 67; CYCLOPHOSPHAMIDE; FLUDARABINE; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M 195; RADIOACTIVE IODINE; RHENIUM 188; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HALF LIFE TIME; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; REVIEW; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

EID: 38349181794     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701679881     Document Type: Review

References (35)

1. Caron, PC, Dumont, L. and Scheinberg, DA. (1998) Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res, 4, pp. 1421-1428.
2. Dinndorf, PA, Andrews, RG and Benjamin, D. (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood, 67, pp. 1048-1053.
3. Nakano, A., Harada, T., Morikawa, S. and Kato, Y. (1990) Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol Jpn, 40, pp. 107-115.
4. Taetle, R., Ostergaard, H., Smedsrud, M. and Trowbridge, I. (1991) Regulation of CD45 expression in human leukemia cells. Leukemia, 5, pp. 309-314.
5. Noworolska, A., Harlozinska, A., Richter, R. and Brodzka, W. (1985) Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series. Br J Cancer, 51, pp. 371-377.
6. Jurcic, JG, Caron, PC and Nikula, TK (1995) Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res, 55, pp. 5908s-10s.
7. Burke, JM, Caron, PC and Papadopoulos, EB (2003) Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant, 32, pp. 549-556.
8. Appelbaum, F., Matthews, D. and Eary, JF (1992) The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation, 54, pp. 829-833.
9. van der Jagt, RH, Badger, CC and Appelbaum, FR (1992) Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res, 52, pp. 89-94.
10. Matthews, DC, Appelbaum, FR and Eary, JF (1999) Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood, 94, pp. 1237-1247.
11. Pagel, J., Gooley, T. and Rajendran, J. (2006) Targeted radiotherapy using 131I-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): The relationships among dosimetry, bone marrow uptake, and relapse. Eur J Nucl Med Mol Imaging, 33, p. S193.
12. Pagel, JM, Appelbaum, FR and Eary, JF (2006) 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood, 107, pp. 2184-2191.
13. Blaise, D., Maraninchi, D. and Michallet, M. (2001) Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood, 97, pp. 3669-3671.
14. Pagel, J., Appelbaum, F. and Sandmaier, B. (2005) 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood, p. 106.
15. Schwartz, MA, Lovett, DR and Redner, A. (1993) Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol, 11, pp. 294-303.
16. Scheinberg, DA, Lovett, D. and Divgi, CR (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol, 9, pp. 478-490.
17. Jurcic, JG. (2000) Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm, 15, pp. 319-326.
18. Jurcic, J. (2000) Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. J Clin Oncol
19. Bunjes, D., Buchmann, I. and Duncker, C. (2001) Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study. Blood, 98, pp. 565-572.
20. Ringhoffer, M., Blumstein, N. and Neumaier, B. (2005) 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: Results of a phase I-II study. Br J Haematol, 130, pp. 604-613.
21. McDevitt, MR, Ma, D. and Lai, LT (2001) Tumor therapy with targeted atomic nanogenerators. Science, 294, pp. 1537-1540.
22. Jurcic, JG, Larson, SM and Sgouros, G. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 100, pp. 1233-1239.
23. Mulford, DA, Scheinberg, DA and Jurcic, JG. (2005) The promise of targeted {alpha}-particle therapy. J Nucl Med, 46, pp. 199S-204S.
24. Waldmann, TA, White, JD and Carrasquillo, JA (1995) Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86, pp. 4063-4075.
25. Zhang, M., Yao, Z. and Zhang, Z. (2006) The anti-CD25 monoclonal antibody 7G7/B6, armed with the {alpha}-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res, 66, pp. 8227-8232.
26. Zhang, M., Yao, Z. and Patel, H. (2007) Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA, 104, pp. 8444-8448.
27. Lin, Y., Pagel, JM and Axworthy, D. (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res, 66, pp. 3884-3892.
28. Yao, Z., Zhang, M. and Garmestani, K. (2004) Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-biotin. Clin Cancer Res, 10, pp. 3137-3146.
29. Zhang, M., Zhang, Z. and Garmestani, K. (2003) Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA, 100, pp. 1891-1895.
30. Pagel, JM, Hedin, N. and Drouet, L. (2006) Conventional and pretargeted radioimmunotherapy using an anti-murine CD45 monoclonal antibody in a syngeneic, disseminated murine leukemia model. Blood, p. 108.
31. Buchmann, I., Bunjes, D. and Kotzerke, J. (2002) Myeloablative radioimmunotherapy with Re-188-anti-CD66 antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm, 17, pp. 151-163.
32. DeNardo, GL, Lamborn, KR and Goldstein, DS (1997) Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer, 80, pp. 2706-2711.
33. Friesen, C., Glatting, G. and Koop, B. (2007) Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res, 67, pp. 1950-1958.
34. Sandmaier, BM, Bethge, WA and Wilbur, DS (2002) Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood, 100, pp. 318-326.
35. Barbet, J., Kraeber-Bodere, F. and Vuillez, JP (1999) Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm, 14, pp. 153-166.